AR and gastric cancer: Experimental studies confirmed that the proliferation inhibition of oridonin on SGC‐7901 cell was related to TNF‐α/AR/TGF‐β signalling pathway axis, which confirmed the prediction of network pharmacology, and elucidated the mechanism of oridonin on gastric cancer (Figure 8).